- Home
- MCRB vs RNXT Comparison
MCRB vs RNXT Comparison
Compare MCRB & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRB | RNXT |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 42.4M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MCRB | RNXT |
|---|---|---|
| Price | $5.49 | $2.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $14.00 | $8.25 |
| AVG Volume (30 Days) | 53.2K | ★ 1.3M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | $789,000.00 | ★ $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | N/A | $279.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $4.32 | $0.70 |
| 52 Week High | $29.98 | $2.59 |
Technical Indicators
Market Signals| Indicator | MCRB | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 55.09 | 60.03 |
| Support Level | $5.31 | $0.83 |
| Resistance Level | $5.65 | N/A |
| Average True Range (ATR) | 0.33 | 0.26 |
| MACD | 0.13 | 0.05 |
| Stochastic Oscillator | 66.03 | 54.41 |
Price Performance
Historical ComparisonAbout MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.